Autem Therapeutics

Hanover, United States Founded: 2022 • Age: 4 yrs
Bioelectric platforms for cancer treatment are developed.

About Autem Therapeutics

Autem Therapeutics is a company based in Hanover (United States) founded in 2022 by Frederico Costa and Michael Choukas.. Autem Therapeutics has raised $11.5 million across 2 funding rounds from investors including Zentynel and Spectra Investments. The company has 10 employees as of December 31, 2023. Autem Therapeutics offers products and services including AutEMsys TM. Autem Therapeutics operates in a competitive market with competitors including Sequana Medical, Novocure, QV Bioelectronics, Ablatus Therapeutics and Mirai Medical, among others.

  • Headquarter Hanover, United States
  • Employees 10 as on 31 Dec, 2023
  • Founders Frederico Costa, Michael Choukas
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Legal Name Autem
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $11.5 M (USD)

    in 2 rounds

  • Latest Funding Round
    $1.5 M (USD), Series A

    Feb 29, 2024

  • Investors
    Zentynel

    & 1 more

  • Employee Count
    10

    as on Dec 31, 2023

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Autem Therapeutics

Autem Therapeutics offers a comprehensive portfolio of products and services, including AutEMsys TM. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Delivers electromagnetic frequencies to balance energy in cancer cells.

People of Autem Therapeutics
Headcount 10-50
Employee Profiles 13
Employee Profiles
People
Andrew Powell
VP, Business Development & Legal Affairs, USA
People
Jack Tuszynski
VP, Medical & Biophysics R&D, Canada
People
Frederico Costa
Founder & CSO, Brazil
People
Ronald Bracken
VP, Regulatory Affairs & Quality Assurance, USA

Unlock access to complete

Funding Insights of Autem Therapeutics

Autem Therapeutics has successfully raised a total of $11.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $1.5 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series A — $1.5M
  • First Round

    (06 Jun 2022)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Feb, 2024 Amount Series A - Autem Therapeutics Valuation

investors

Jun, 2022 Amount Series A - Autem Therapeutics Valuation Zentynel
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Autem Therapeutics

Autem Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Zentynel and Spectra Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Zentynel is focused on investing in biotechnology companies.
Founded Year Domain Location
Diversified asset management services are offered to clients in Brazil.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Autem Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Autem Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Autem Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Autem Therapeutics

Autem Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sequana Medical, Novocure, QV Bioelectronics, Ablatus Therapeutics and Mirai Medical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Implantable battery-powered pumps for ascites removal are developed.
domain founded_year HQ Location
Therapeutics for solid tumors are developed via Tumor Treating Fields.
domain founded_year HQ Location
Electrotherapy devices for brain tumor treatment are manufactured.
domain founded_year HQ Location
Develops innovative devices for bimodal electric tissue ablation.
domain founded_year HQ Location
Mirai Medical is focused on transforming gastrointestinal disease treatment.
domain founded_year HQ Location
Liver dialysis devices for treating cirrhosis and failure are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Autem Therapeutics

Frequently Asked Questions about Autem Therapeutics

When was Autem Therapeutics founded?

Autem Therapeutics was founded in 2022.

Where is Autem Therapeutics located?

Autem Therapeutics is headquartered in Hanover, United States. It is registered at Hanover, New Hampshire, United States.

Who is the current CEO of Autem Therapeutics?

Michael Choukas is the current CEO of Autem Therapeutics. They have also founded this company.

Is Autem Therapeutics a funded company?

Autem Therapeutics is a funded company, having raised a total of $11.5M across 2 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Jun 06, 2022.

How many employees does Autem Therapeutics have?

As of Dec 31, 2023, the latest employee count at Autem Therapeutics is 10.

What does Autem Therapeutics do?

Autem Therapeutics was founded in 2022 and is based in Hanover, United States. Bioelectric technology and oncology therapeutics are developed by the company. A bioelectric platform called AutEMsys is being created to provide personalized, amplitude-modulated electromagnetic frequencies. These are targeted at hepatocellular carcinoma and other solid tumor cancers. Operations focus on advancing non-invasive treatment options in the biotechnology sector.

Who are the top competitors of Autem Therapeutics?

Autem Therapeutics's top competitors include Sequana Medical, Novocure and QV Bioelectronics.

What products or services does Autem Therapeutics offer?

Autem Therapeutics offers AutEMsys TM.

Who are Autem Therapeutics's investors?

Autem Therapeutics has 2 investors. Key investors include Zentynel, and Spectra Investments.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available